Less noise means more discovery: Jumpcode Genomics CRISPRclean technology removes the noise—so you can easily find the genetic information you care about.

At Jumpcode Genomics, we are focused on breaking the technical barriers limiting genomics today. Our patented technology unlocks the power of next-generation sequencing by improving sensitivity, reducing costs, simplifying workflows and removing bias. We are empowering scientists to extract greater insights and detect novel signals that were previously hidden by abundant and uninformative sequences. Researchers worldwide are using Jumpcode’s CRISPRclean technology in the fields of basic research, infectious disease, oncology and consumer genomics.


Our leadership team is passionate about what we do and who we are as a company. They are proven life-science leaders with experience and connections across the industry and in the global scientific community.

Yaron Hakak - Jumpcode CEO

Yaron Hakak


A biotech industry veteran, Yaron Hakak recently served as director of business development at Illumina, where he supported the company’s research and applied markets for NGS. Prior to Illumina, he was director of business development at Affymetrix, focused on corporate activities related to its genomics and proteomic product portfolios. Dr. Hakak also held positions at Arena Pharmaceuticals, where he managed genomics research for target identification and led discovery biology programs.

Brandon Poe - Jumpcode CFO

Brandon Poe


Brandon brings 25 years of financial experience to Jumpcode across various industries, including life sciences, medical device and genomics services. Most recently, he was CFO at Genome Medical, a genomic telehealth provider, where he led all aspects of finance. Prior to Genome Medical, Brandon was VP of Finance at Illumina, a genomic tools company, Chief Financial Officer at Sotera Wireless, a medical device start-up, and VP of Finance at Inverness Medical Innovations (formerly Biosite), a point-of-care diagnostics company acquired by Abbott. He received his bachelor’s degree from Bucknell University and MBA from the University of Chicago Booth School of Business.

Jon Bell - Jumpcode VP of Sales

Jon Bell

VP of Sales

Jonathan Bell joined Jumpcode with deep commercial experience in driving the growth of disruptive genomic technologies. He has held positions with progressively increasing responsibilities in the areas of sales, product marketing and regional marketing for life sciences companies, including Affymetrix, Illumina and 10x Genomics. Jonathan most recently served as a Vice President for Celsee (acquired by Bio-Rad).

Kerri McWeeny - Jumpcode VP of Marketing

Kerri McWeeny

VP of Marketing

Kerri McWeeny joined Jumpcode from Illumina, where she most recently served as a Senior Director in marketing. Kerri joined Illumina in 2012, holding leadership roles in global pricing strategy, marketing strategy and communications throughout her tenure. Prior to Illumina, she held commercial leadership roles at MO BIO Laboratories and GenVault Corp, as well as research and development roles at Motorola Life Sciences and Abbott Laboratories.

Jon Armstrong - Jumpcode VP of R&D

Jon Armstrong

VP of R&D

Jon Armstrong joined Jumpcode Genomics as Vice President of Research and Development. Most recently, Jon served as Chief Scientific Officer for Cofactor Genomics, a predictive immune modeling company, which he cofounded. In this role, Jon led product launches for more than a dozen genomics solutions for the research and clinical space. Prior to Cofactor Genomics, Jon spent nearly a decade in Elaine Mardis’ lab at The Washington University Genome Institute, where he helped develop technologies in microarray, next-generation sequencing, molecular biology and cancer genetics.

Board Members

Yaron Hakak

Frank Witney

Kirk Malloy

Dan Kidle
Arboretum Ventures

Michael Liang
Baird Capital

Court Turner
Lyzz Capital

Scientific Advisory Board

Gene Yeo

Shawn Levy
Element Bio

Stan Nelson

Nik Schork

Andrew Su